Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function

详细信息    查看全文

• 作者：Inmaculada Hernandez ; PharmD ; PhD^a ; Kenneth J. Smith ; MD ; MS^c ; Yuting Zhang ; PhD^b ; ^{ytzhang@pitt.edu}
• 关键词：Anticoagulation ; Atrial fibrillation ; Cost-effectiveness ; Non-vitamin K antagonist oral anticoagulants
• 刊名：Thrombosis Research
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：150
• 期：Complete
• 页码：123-130
• 全文大小：410 K
• 卷排序：150

文摘

We compared the cost-effectiveness of NOACs and warfarin from the US perspective. We modeled a cohort of atrial fibrillation patients at high-risk of bleeding. For CrCl between 50 and 95 ml/min, edoxaban was most cost-effective. Apixaban would be cost-effective if its price was reduced by 1.3%. For CrCl > 95 ml/min, apixaban was the most cost-effective treatment.